Month: September 2026

As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks

Application expands Artelo’s intellectual property position for ART27.13 into obesity, where J.P. Morgan has projected the global GLP-1 market could reach $200 billion by 2030

New findings show the combination further improved oral glucose tolerance and increased bone mineral density, an effect not observed in any other treatment group

SOLANA BEACH, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with obesity, cancer, pain, dermatologic and neurological conditions, today announced the filing of a provisional patent application covering the use of ART27.13 for the treatment of obesity. The application covers ART27.13 both as a monotherapy and in combination with GLP-1 receptor agonists such as semaglutide, the active ingredient in Ozempic^® and Wegovy^®.

The filing follows unexpected findings from Artelo’s nonclinical DIO-2 study that point to a potentially broader role for ART27.13 in weight and metabolic regulation. The Company is disclosing additional findings from the study today, alongside results reported on September 16, 2026.

As previously reported, ART27.13 monotherapy produced approximately 20% weight loss from baseline over four weeks in obese mice, comparable to semaglutide. In combination with semaglutide, obese mice lost approximately 40% of their baseline body weight. Approximately 80% of the weight lost in ART27.13-treated groups was fat, compared with approximately 70% with semaglutide alone.

The new findings show that the combination suppressed appetite more than semaglutide alone and further improved oral glucose tolerance. Bone mineral density increased in the combination group, an effect not observed in any other treatment group. Semaglutide and ART27.13 each reduced total cholesterol, LDL and HDL to similar extents, with greater reductions when given together. Liver hypertrophy was reduced across all treatment groups.

“These findings were unexpected and potentially expand the opportunity for ART27.13 well beyond our original hypothesis,” said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “We began studying ART27.13 alongside semaglutide because our published cancer cachexia research with Professor Richard Porter of Trinity College Dublin indicated it helps preserve muscle. We observed substantial weight loss with ART27.13 on its own, an approximate doubling of weight loss in combination with a semaglutide, and a set of metabolic and bone findings we did not anticipate. This application secures an early filing date for that work while we pursue it.”

ART27.13 is a peripherally restricted dual cannabinoid CB₁ and CB₂ receptor agonist. The Company believes the findings are particularly novel because historical research into cannabinoid signaling for obesity has largely focused on CB₁ antagonism. ART27.13 had no observed effect on any measured parameter in lean animals maintained on standard chow, a pattern Artelo believes is consistent with a metabolic regulator profile. Artelo plans to investigate the mechanisms behind these effects, including ART27.13’s potential impact on key pathways and hormones involved in appetite and metabolic regulation.

Rather than competing with GLP-1 therapies, ART27.13 is being evaluated as a potential complement to them, with the aim of improving both the magnitude and the quality of weight loss. ART27.13 enters obesity research with an existing clinical dataset: six completed clinical studies, two ongoing clinical trials, and nearly 300 participants receiving ART27.13 to date.

“Bone and lean mass are drawing growing attention as GLP-1 therapies are used more widely, so seeing bone mineral density increase in the combination group was notable,” added Mr. Gorgas. “The potential to enhance an established GLP-1 therapy while showing meaningful activity as a monotherapy is expected to create a new development path for ART27.13, and we intend to protect it as the science advances.”

About ART27.13

Initially developed by AstraZeneca plc, ART27.13 is a dual cannabinoid agonist that has been evaluated in six clinical studies and two ongoing clinical trials with nearly 300 participants. It is being developed as a once-daily oral agent that selectively targets peripheral CB₁ and CB₂ receptors, enabling systemic metabolic effects while minimizing central nervous system-mediated toxicity.

Artelo is conducting a Phase 2 trial, the Cancer Appetite Recovery Study (CAReS), evaluating ART27.13 as a supportive care therapy for cancer patients with anorexia and weight loss. Patients had to have lost at least 5% of body weight to enroll. In interim data, those titrated to the highest dose (1300 µg) gained an average of 6% of body weight over 12 weeks, while patients on placebo lost an additional ~5%. There is currently no FDA-approved treatment for cancer anorexia cachexia syndrome. ART27.13 is also being evaluated in DREAM, a Phase 2 study in people with glaucoma investigating whether oral daily treatment can lower intraocular pressure.

About the Diet-Induced Obesity (DIO) Model

The DIO-2 study evaluated ART27.13 in mice with diet-induced obesity, the standard nonclinical model used across the industry to evaluate GLP-1 receptor agonists and other anti-obesity therapies. Obese mice maintained on a high-fat diet were treated with vehicle, semaglutide (20 nmol/kg) s.c., ART27.13 (2.5 µmol/kg) orally, or semaglutide in combination with ART27.13 under three dosing regimens. Lean mice maintained on standard chow were treated with vehicle or ART27.13 to assess effects in non-obese animals. Body weight and food consumption were measured throughout the four-week treatment period, and body composition was assessed by DEXA and MRI imaging. The findings replicate and extend the results of an initial pilot study (DIO-1) in the same model, in which co-treatment with ART27.13 was observed to improve the weight-loss efficacy when used in combination with semaglutide.

Ozempic^® and Wegovy^® are registered trademarks of Novo Nordisk A/S. Artelo Biosciences is not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S.

About Artelo Biosciences

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in obesity, anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, and commercial expertise to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including but not limited to: our ability to raise additional capital in the future; the inherent uncertainties of preclinical and clinical research, including the possibility that results observed in nonclinical animal models may not be predictive of, or replicated in, human clinical trials; the preliminary nature of the study results described in this press release, which remain subject to completion of the full analysis; the early stage of our obesity research program; the uncertainty of patent protection and the potential for intellectual property challenges; the fact that a provisional patent application does not itself result in an issued patent, confers no enforceable rights, and must be followed by a non-provisional application within 12 months to preserve its priority date; the highly competitive nature of the pharmaceutical industry, including the GLP-1, obesity and combination therapy markets; the risk that third-party market projections may not materialize or that the Company may not be able to participate in projected market opportunities; and our ability to enter into partnering or licensing arrangements on acceptable terms, or at all. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:

Crescendo Communications, LLC

Tel: 212-671-1020

Email: ARTL@crescendo-ir.com

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — Brutus Mining Inc. (“Brutus” or the “Company”) (CSE: BRU) (FSE: ZI3) is pleased to announce its common shares are now trading on the Frankfurt Stock Exchange (“FSE”) under the symbol “ZI3”, WKN: A42M2A and ISIN: CA1169151091.

The Company’s common shares are now cross-listed on the Canadian Securities Exchange and on the FSE, providing international exposure to both Canadian and European investors. The Company’s FSE stock quote link can be found here: https://live.deutsche-boerse.com/equity/bru-mng-inc-o-n?mic=XFRA

Christos Doulis, Chief Executive Officer of Brutus Mining, commented, “Germany has a long-established investor base for junior copper and gold exploration. The FSE listing puts Brutus in front of it as we begin work at the CW Property. CW is a road-accessible copper-gold project in British Columbia, with five documented mineral occurrences across a single contiguous land package.”

About Brutus Mining Inc.

Brutus Mining Inc. (CSE: BRU | FSE: ZI3) is a Vancouver-based mineral exploration company. Its sole asset is an option to acquire a 100% interest in the CW Property, five contiguous mineral claims totalling 2,894.56 hectares in the Kamloops Mining Division of south-central British Columbia, approximately 100 kilometres north of Kamloops. The Property hosts five documented MINFILE mineral occurrences with copper and gold mineralization and is at an early stage of exploration.

On Behalf of the Board of Directors

Christos Doulis
Chief Executive Officer, Director
Telephone: +1 (604) 636-7335
Email: info@brutusmining.com

Disclaimer for Forward-Looking Information

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward-looking statements or information.

Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Maxus’, future growth potential for Maxus and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of copper, gold, tungsten, antimony and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Maxus’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

This news release contains “forward-looking information” within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the potential benefits of listing on the FSE. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of well results and the geology, continuity and grade of copper, gold, tungsten, antimony and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

COLDWATER, Mich., Sept. 23, 2026 (GLOBE NEWSWIRE) — The Board of Directors of Southern Michigan Bancorp, Inc. (OTC Pink: SOMC) declared a quarterly dividend of $0.17 per share on the outstanding shares of the corporation’s stock. The dividend is payable on October 16, 2026, to shareholders of record October 5, 2026. The annualized cash dividend of $0.68 per share represents a 2.19% dividend yield based on the current market price of $31.00 per share.

Southern Michigan Bancorp, Inc. is a bank holding company and the parent company of Southern Michigan Bank & Trust. It operates 18 offices within Branch, Calhoun, Hillsdale, Jackson, Kalamazoo, and St. Joseph Counties providing a broad range of consumer, business, and wealth management services throughout the region. For more information, please visit the Southern Michigan Bank & Trust website, www.smb-t.com. 

This press release contains forward-looking statements that are based on management’s beliefs, assumptions, current expectations, estimates and projections about the financial services industry, the economy, and Southern Michigan Bancorp, Inc. Although we currently expect to continue to pay a quarterly cash dividend, each future dividend will be considered and declared by the board of directors in its discretion. Whether the board of directors continues to declare dividends depends on a number of factors, including our future financial condition and profitability. Forward-looking statements are based upon current beliefs and expectations and involve substantial risks, uncertainties, and assumptions (“risk factors”), which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. We undertake no obligation to update or revise our forward-looking statements to reflect developments that occur, or information obtained after the date of this report.

CONTACT: CONTACT: 
John Waldron, President & CEO
(517) 279-5500

WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave’s INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 alone 

Maintenance clinical trial evaluating WVE-007’s ability to curtail weight regain after incretin cessation on track to initiate 2H 2026

CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the initiation of its Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA, in combination with tirzepatide in adults living with obesity.

“This combination trial of WVE-007 with weekly tirzepatide marks an important milestone in our development plan to advance WVE-007 across three distinct obesity treatment settings: monotherapy, combination therapy, and as a post-incretin maintenance therapy to prevent weight recurrence,” said Christopher Wright, MD, PhD, Chief Medical Officer at Wave Life Sciences. “Our preclinical data, as well as emerging clinical data in the field, support the potential for enhanced fat loss and preservation of muscle with WVE-007 as compared to incretins alone. The consequence of muscle loss is particularly important since beyond strength, skeletal muscle also plays an important role in both metabolism and weight maintenance. In our clinical data to date, we have demonstrated a differentiated profile for WVE-007, with potential for best-in-class INHBE silencing, favorable safety and tolerability, and once- or twice-yearly dosing.”

The INLIGHT™ clinical program is evaluating WVE-007 as a monotherapy and in combination with tirzepatide as a treatment for obesity and other cardiometabolic indications, including MASH. The placebo-controlled (3:1) Phase 2a combination trial will evaluate 240 mg and 400 mg doses of WVE-007 in combination with weekly tirzepatide in individuals living with obesity (BMI 35-50 kg/m²) and type 2 diabetes. The INLIGHT™ clinical program also includes an ongoing Phase 2a monotherapy trial, which includes multiple assessments over a 12-month period, and these results will inform further development of WVE-007 in obesity, as well as MASH, type 2 diabetes, and cardiovascular disease.

Wave also remains on track to initiate a clinical trial of WVE-007 as a maintenance therapy to preserve weight loss following discontinuation of incretin treatment in the second half of 2026.

Wave previously presented preclinical data at ObesityWeek® 2025 demonstrating that WVE-007 has potential for use synergistically with GLP-1s as well as to curtail weight regain after the cessation of treatment with GLP-1.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements concerning our goals, beliefs, expectations, strategies, objectives and plans, and other statements that are not necessarily based on historical facts, including statements regarding the following, among others: the anticipated initiation, site activation, patient recruitment, patient enrollment, dosing, generation and reporting of data and/or completion of our INLIGHT clinical trial and the timing and announcement of such events; our expectations to initiate new clinical trials evaluating WVE-007 for post-incretin maintenance, and the expected results and timing thereof; the potential of WVE-007’s mechanism (INHBE GalNAc-siRNA) as a meaningful and differentiated therapeutic approach for obesity as well as the potential to develop WVE-007 for other indications, including MASH, type 2 diabetes, and cardiovascular disease; the future performance and results of WVE-007 in the Phase 2a portions of our INLIGHT clinical trial, including our expectations that there will be even greater improvements in body composition in individuals with higher BMI, visceral fat and body fat at baseline; the potential benefits of our toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), compared to others; the benefits of RNA medicines generally; and the potential for certain of our programs to be best-in-class. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual results to differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — Aventis Energy Inc. (“Aventis” or the “Company”) (CSE: AVE | FRA: C0O0 | OTC: VBAMF) is pleased to announce that its board of directors has approved a consolidation (the “Consolidation”) of the common shares of the Company (“Common Shares”) on a ten-to-one basis. The Company has 94,248,477 Common Shares outstanding and, if completed, the proposed Consolidation would reduce the issued and outstanding Common Shares to approximately 9,424,844 Common Shares.

The Company will issue a subsequent news release, following its filing of all necessary documentation with the Canadian Securities Exchange (“CSE”) in respect of the proposed Consolidation, announcing the effective date of the proposed Consolidation, the new CUSIP and ISIN for the consolidated Common Shares and any other relevant details regarding the proposed Consolidation. No fractional Common Shares will be issued as a result of the proposed Consolidation. Any fractional shares resulting from the Consolidation will be rounded down to the next whole Common Share, and no cash consideration will be paid in respect of fractional shares.

The Company’s board of directors believes that the Consolidation will provide the Company with greater flexibility for the continued development of its business and the growth of the Company, including financing arrangements. There is no change of business associated or being effected with respect of the Consolidation. In addition, the Company will not be changing its name or stock symbol during the Consolidation.

About Aventis Energy Inc.

Aventis Energy Inc. (CSE: AVE | FRA: C0O0 | OTC: VBAMF) is a mineral exploration company dedicated to the development of strategic projects comprised of battery, base and precious metals in stable jurisdictions. The Company is working to advance its Corvo Uranium & Sting Copper Project.

The Corvo Uranium property has historical drill holes intersected multiple intervals of uranium mineralization, notably along a strike length of 800 metres between historical drill holes TL-79-3 (0.116% U₃O₈ over 1.05 m) and TL-79-5 (0.065% U₃O₈ over 0.15 m)². High-grade* Uranium at Surface with the Manhattan showing (with outcrop samples grab samples returning up to 8.10% U₃O₈) and SMDI showing 2052 (0.137% U₃O₈ and 2,300 ppm Th).

The Sting Copper Project covers approximately 3,700 hectares and recently had results of 54.8m at 0.32% Cu starting at a depth of 27.0m, with higher-grade intervals including six samples (≥0.5m length) ranging from 0.96% to 5.43% Cu. High grade samples of 0.5m at 2.85% Cu and 0.5m at 1.92% Cu with an additional broader interval of 31.1m at 0.27% Cu.

On Behalf of the Board of Directors

Michael Mulberry
Chief Executive Officer, Director
+1 (604) 229-9772
info@vitalbatterymetals.com

Disclaimer for Forward-Looking Information

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward-looking statements or information.

Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Aventis, future growth potential for Aventis and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of uranium, copper, gold and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Aventis’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

This news release contains “forward-looking information” within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the proposed Consolidation, including the proposed consolidation ratio, the anticipated effective date of the Consolidation and the anticipated effect of the Consolidation on trading in the Common Shares. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of well results and the geology, continuity and grade of uranium, copper, gold and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

The Canadian Securities Exchange (CSE) does not accept responsibility for the adequacy or accuracy of this release.

Ellis Jacob to Serve as Special Advisor to the Board

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — (TSX: CGX) – Cineplex Inc. (“Cineplex” or the “Company”), Canada’s leading entertainment and media company, announces the appointment of Bill Walker as Chief Executive Officer, effective today, following a comprehensive Board-led succession process initiated after the announcement last year that Ellis Jacob would retire from Cineplex.

The Company also announced that its board of directors (the “Board”) has initiated a review of strategic alternatives (the “Strategic Review”) to evaluate opportunities to enhance and maximize value for all shareholders.

To support a seamless leadership transition and the Strategic Review process, Ellis Jacob will serve as Special Advisor to the Board through December 31, 2026, working closely with the Board, management team and the Company’s advisors in connection with the review and assessment of strategic alternatives available to the Company.

Appointment of Bill Walker as Chief Executive Officer
After a robust and well-governed succession process that included both an extensive global search and consideration of internal candidates, the Board selected Bill Walker to lead Cineplex.

Walker is a highly respected retail and entertainment executive with extensive leadership experience across the cinema exhibition, real estate and retail sectors. He previously served as Chief Executive Officer of Landmark Cinemas, Canada’s second-largest theatre exhibitor, operating as part of Kinepolis Group NV (“Kinepolis”), a publicly traded cinema company based in Belgium.

During his nine-year tenure at Landmark, Walker established a strong track record of disciplined capital allocation, operational excellence and guest experience innovation. He also played a key leadership role in Landmark’s successful sale to Kinepolis in 2017 and subsequently continued to lead the Canadian business under Kinepolis’ public company ownership. He is widely known throughout the Canadian exhibition industry and has developed long-standing relationships with exhibitors, distributors and business partners across North America.

“The Board’s responsibility is to ensure that Cineplex is positioned to create long-term value for shareholders,” said Phyllis Yaffe, Chair of the Board of Cineplex. “Following a comprehensive succession process, we are delighted to appoint Bill Walker as the Company’s next Chief Executive Officer. Bill brings a unique combination of industry expertise, operational leadership, transaction experience and strategic perspective. Given his deep understanding of the theatrical exhibition industry and proven leadership experience, the Board is confident that Bill is exceptionally well positioned to lead Cineplex. At the same time, the Board believes it is appropriate to conduct a comprehensive review of strategic alternatives available to the Company. The appointment of Bill and the commencement of this review will provide the Company with leadership continuity and strategic flexibility to ensure shareholders benefit from the Company’s full potential.”

“I am honoured to join Cineplex at this important time in the Company’s history,” said Walker. “Cineplex is one of Canada’s most recognized and admired consumer brands, supported by outstanding employees and industry-leading assets. Throughout the recruitment process, I became increasingly excited about the Company’s future prospects and the opportunity to help lead its next chapter. Having spent much of my career in the exhibition industry, I have great respect for what the Cineplex team has built. I believe the Company possesses an exceptional platform for growth, a powerful brand and meaningful opportunities to create value. I fully support the Board’s commitment to evaluating strategic alternatives and look forward to working closely with the Board, management team and other stakeholders as the Strategic Review progresses. Regardless of the outcome of the Strategic Review, my focus will be on driving operational excellence, delivering exceptional guest experiences and superior outcomes for shareholders.”

Board Commences Strategic Review
The Board has initiated a Strategic Review to evaluate opportunities to enhance and maximize value for all shareholders. As part of the Strategic Review, the Board will consider a range of alternatives, including, but not limited to, a potential sale of the Company. 

The Board has engaged Goldman Sachs and TD Securities as co-financial advisors in connection with the Strategic Review. The Company has also retained Goodmans LLP as legal counsel.

The Strategic Review will be conducted under the oversight of the Board, working closely with Ellis Jacob in his capacity as Special Advisor to the Board, and with the assistance of the Company’s financial and legal advisors and senior management.

“The Board recognizes its responsibility to continuously evaluate opportunities to enhance shareholder value,” said Yaffe. “Cineplex has a strong market position, a portfolio of leading entertainment assets, powerful consumer brands, and attractive long-term growth opportunities. However, we believe the Company’s current market valuation may not fully reflect the strength of its business and long-term prospects. While we remain highly confident in the Company’s future prospects, we are committed to evaluating all available opportunities and remain open-minded regarding potential outcomes.”

The Board and management team remain committed to executing the Company’s strategic priorities and continuing to grow the business while the Strategic Review is underway. Cineplex remains focused on serving its guests, investing in its businesses and delivering long-term value for shareholders. 

No decisions have been made regarding any particular strategic alternative, and no timetable has been established for completion of the Strategic Review. There can be no assurance that the Strategic Review will result in any transaction, agreement or other strategic outcome. The Company does not intend to disclose developments relating to the Strategic Review unless and until it determines that disclosure is appropriate or required under applicable securities laws.

Ellis Jacob to Continue as Special Advisor to the Board
To support both the leadership transition and the Strategic Review, Ellis Jacob will remain actively involved with the Company through December 31, 2026 as Special Advisor to the Board. In this capacity, he will provide strategic counsel to the Board and assist in the evaluation of strategic alternatives available to the Company.

Jacob has served as President and Chief Executive Officer of Cineplex and its predecessor organizations for more than three decades and has played a central role in building Cineplex into Canada’s leading entertainment and media company.

“On behalf of the Board, I would like to thank Ellis for his extraordinary leadership, entrepreneurial vision and unwavering commitment to Cineplex,” said Yaffe. “Given his unparalleled knowledge of the business, longstanding industry relationships and exceptional track record of value creation, the Board believes Ellis’ continued involvement will be highly valuable as we advance both the leadership transition and the Strategic Review and work toward achieving the best possible outcome for shareholders.”

“It has been a privilege to lead Cineplex and work alongside the exceptional people who have helped build this Company over many years,” said Jacob. “I support the Board’s appointment of Bill Walker and its decision to undertake a comprehensive review of strategic alternatives. Cineplex has built an incredible portfolio of assets, a diversified business model, market-leading brands and strong stakeholder relationships. I look forward to continuing to work closely with the Board and our advisors as we evaluate opportunities to unlock value for shareholders.”

Cineplex
Cineplex (TSX:CGX) is a top-tier Canadian brand that operates in the Film Entertainment and Content, Amusement and Leisure, and Media sectors. Cineplex offers a unique escape from the everyday to millions of guests through its circuit of 168 movie theatres and location-based entertainment venues. In addition to being Canada’s largest and most innovative film exhibitor, the Company operates Canada’s favourite destination for ‘Eats & Entertainment’ (The Rec Room), complexes specially designed for teens and families (Playdium), and an entertainment concept that brings movies, amusement gaming, dining, and live performances together under one roof (Cineplex Junxion). It also operates successful businesses in cinema media (Cineplex Media), alternative programming (Cineplex Events) and motion picture distribution (Cineplex Pictures). Providing even more value for its guests, Cineplex is a partner in Scene+, Canada’s largest entertainment and lifestyle loyalty program.

Proudly recognized as having one of the country’s Most Admired Corporate Cultures, Cineplex employs over 10,000 people in its offices and venues across Canada. To learn more, visit Cineplex.com.

Caution Regarding Forward-Looking Statements
Certain statements and/or information in this news release (identified by words such as “may”, “will”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective” and “continue” (or the negative thereof)), and words and expressions of similar import, and similar expressions suggesting future events or future performance are intended to identify forward-looking statements. Such forward-looking statements are based on expectations and assumptions made by Cineplex and are subject to risks and uncertainties which may be beyond Cineplex’s control. Specifically, statements with respect to the Company’s current expectations regarding the Strategic Review are forward-looking statements.  There can be no assurance that the Strategic Review will result in any transaction, agreement or other strategic outcome.  A comprehensive discussion of risks that may impact Cineplex can be found in Cineplex’s public reports and filings, including those described in Cineplex’s Annual Information Form (“AIF”), and Management’s Discussion and Analysis for the year ended December 31, 2025 (“Annual MD&A”), which are both available under the Company’s profile on Sedar+ (www.sedarplus.ca). The foregoing list of factors that may affect future operations and results is not exhaustive. Readers are cautioned that undue reliance should not be placed on forward-looking statements as actual operations and results may vary materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. Cineplex does not undertake to update, correct or revise any forward-looking statements as a result of any new information, future events or otherwise, except as may be required by applicable law.

Investors:
Mahsa Rejali
Vice President, Corporate Development and Investor Relations
InvestorRelations@Cineplex.com

Media:
Michelle Saba, CPIR
Vice President, Communications
PressRoom@Cineplex.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7b811234-75dc-4b65-90ab-17dad6b7cdf8

Vancouver, BC, Sept. 23, 2026 (GLOBE NEWSWIRE) — Deep Sea Minerals Corp. (CSE: SEAS) (OTCQB: DSEAF) (FSE: X450) (“Deep Sea Minerals” or the “Company”), a subsea mineral exploration and development company focused on advancing critical mineral opportunities from the deep ocean, is pleased to announce that it has entered into a non-binding and non-exclusive letter of intent (the “LOI”) with Westwin Elements, Inc. (“Westwin”) regarding a proposed joint development agreement to evaluate potential U.S.-based processing routes for polymetallic nodules.

The LOI establishes a framework for the parties to negotiate a definitive joint development agreement in the future, following, among other things, the Company obtaining subsea mineral rights and all licenses, permits and other regulatory approvals required to explore, recover, test mine and harvest subsea polymetallic nodules. Such a joint development agreement would establish a formal framework for the Company and Westwin to jointly evaluate processing and recovery pathways for nickel, cobalt, copper, and manganese contained in polymetallic nodules. Any future joint development, feedstock supply, offtake or commercial processing arrangement would remain subject to further negotiation, applicable conditions and the execution of definitive agreements. There can be no assurance that the Company ever obtains subsea mineral rights or enters into any joint development or other definitive agreement with Westwin.

The LOI, or any future joint development or other definitive agreement with Westwin, is not intended to replace, modify or otherwise affect Westwin’s existing feedstock relationships or arrangements with third parties.

Proposed Joint Technical Evaluation

The LOI contemplates that, under any future joint development agreement with Westwin, the Company would provide representative polymetallic nodule samples and available geological and geochemical data for evaluation and Westwin would undertake bench-and pilot-scale test work to assess potential processing routes. The proposed joint development program would assess the principal processing steps from polymetallic nodule material through intermediate and potential saleable products, with the objective of developing a recommended processing route and process block flowsheet.

Under the LOI, the Company is responsible for the costs associated with providing samples and related data, while Westwin is responsible for the costs of test work conducted at its facilities, unless otherwise agreed by the parties.

The parties contemplate that the proposed technical evaluation would assess whether polymetallic nodules could represent an additional potential feedstock source for future U.S.-based critical mineral processing capacity.

“Evaluating potential downstream processing pathways is an important part of our work to understand how polymetallic nodules could ultimately fit within a U.S.-based critical minerals supply chain,” said James Deckelman, Chief Executive Officer of Deep Sea Minerals Corp. “This non-binding arrangement with Westwin provides a framework for future discussions of a joint development agreement to evaluate the technical work required to assess potential processing routes. The current focus is on technical evaluation, and any future commercial relationship would remain subject to applicable conditions and the negotiation and execution of definitive agreements.”

“Westwin’s potential collaboration with Deep Sea Minerals is an important development towards strengthening the nation’s critical mineral supply chain,” said KaLeigh Long, founder and CEO of Westwin. “By evaluating new potential sources of critical mineral feedstock alongside domestic processing capabilities, we are working to expand the options available to support U.S. national security and resilience. We look forward to bringing Westwin’s processing expertise to this potential collaboration and exploring the potential of polymetallic nodules as an additional domestic resource.”

Potential Future Feedstock Relationship 

If the parties enter into a definitive joint development agreement in the future, and the contemplated technical program identifies a processing route that the parties determine to be technically and commercially viable, the Company and Westwin may consider a longer-term commercial relationship involving the Company supplying Westwin with polymetallic nodule feedstock. Any future supply arrangement would remain subject to, among other things, successful technical evaluation, applicable funding conditions, the Company obtaining the required exploration and/or commercial recovery rights and regulatory approvals, sufficient processing capacity, commercial viability and the negotiation and execution of definitive agreements. The Company has not committed to provide Westwin with any minimum quantity of polymetallic nodule material, and neither party currently has any binding supply, offtake or commercial processing obligation. There can be no assurance that any ongoing commercial relationship with Westwin will ever materialize or that the Company will ever be able to provide a commercial supply of polymetallic nodule feedstock.

Other Corporate Updates

The Company intends to enter into a third extension of its investor relations and marketing agreement with Capital Gain Media Inc. (“CGM”), originally announced on February 24, 2026, and previously extended June 4 and July 9, 2026, subject to the approval of the Canadian Securities Exchange (the “CSE”). Under the proposed extension, CGM would continue to provide investor awareness, digital marketing, content development, and related communication services in support of the Company’s capital markets initiatives. The extension would continue for up to 90 days, or until the allocated marketing budget has been exhausted. The Company intends to allocate an additional marketing budget of US$100,000, plus applicable taxes, for the extended term.

CGM has a business address located at 1111 West Hastings Street, 15th Floor, Vancouver, V6E 2J3 and its principal Graham Colmer can be contacted at admin@capitalgainmedia.com. CGM and its principals are arm’s length from the Company.

ABOUT WESTWIN ELEMENTS, INC.

Westwin Elements is scaling America’s only Class 1 nickel refinery, delivering high-purity Class 1 nickel and specialized nickel products for national security and industrial applications. Using carbonyl refining technology, Westwin is driving critical mineral independence and reshaping the future of sustainable metal refining.
​
For more information, visit www.westwinelements.com.

ABOUT DEEP SEA MINERALS CORP.

Deep Sea Minerals Corp. is a subsea mineral exploration and development company focused on evaluating opportunities to support the future supply of critical minerals through the acquisition, exploration, and development of deep-sea mineral assets.

The Company’s strategy is centered on identifying jurisdictions and geological settings with potential exposure to polymetallic nodule systems, which are recognized for containing combinations of metals that may be relevant to defense, industrial manufacturing, clean energy infrastructure, advanced electronics, and artificial intelligence-related supply chains. These seabed resources represent a largely undeveloped component of the global mineral supply base and are the subject of increasing policy, scientific, and regulatory attention worldwide.

As part of this process, the Company has commenced early-stage engagement with selected governments and regulatory bodies in the Pacific Ocean region to assess potential pathways for future exploration initiatives, subject to applicable international, national, and environmental frameworks.

For further information, please see the Company’s website: https://www.deepseamineralscorp.com

SOCIAL MEDIA

Facebook: https://www.facebook.com/deepseacorp/
Instagram: https://www.instagram.com/deepseacorp
X: https://x.com/deepseacorp
LinkedIn: https://www.linkedin.com/company/deepseacorp
Youtube: https://www.youtube.com/@deepseacorp

ON BEHALF OF THE BOARD
“James A. Deckelman”
James A. Deckelman, Chief Executive Officer

For further information, please contact: 
James A. Deckelman
Chief Executive Officer
Phone: 1-281-467-1279
Email: info@deepseamineralscorp.com

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved the contents of this press release.

Forward-Looking Statements

This news release contains certain forward-looking statements and forward-looking information (collectively, “forward-looking statements”) that relate to the Company’s current expectations and views of future events. In some cases, these forward-looking statements can be identified by words or phrases such as “may”, “might”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “plan”, “indicate”, “seek”, “believe”, “predict” or “likely”, or the negative or grammatical variations of these terms, or other similar expressions intended to identify forward-looking statements, although not all forward-looking statements include such words. The Company has based these forward-looking statements on its current expectations and projections about future events and financial trends that it believes might affect its financial condition, results of operations, business, prospects and financial needs. Forward-looking statements contained in this news release include, but are not limited to, statements about: the Company’s plans and strategies, including the potential acquisition of subsea mineral exploration or exploitation rights; any future joint development or other definitive agreement with Westwin; the execution of a joint development program; the successful identification of a technically and commercially viable processing route; any supply or other agreement with Westwin; the Company’s ability to supply polymetallic nodule feedstock; and the Company’s third extension of its agreement with CGM.

This forward-looking information and other forward-looking information are based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Material factors underlying forward-looking information and management’s expectations include certain assumptions in respect of, among other things: favourability of operating conditions; the receipt of necessary third party approvals, licences or permits on favourable terms; the result of any potential legal, regulatory or geopolitical conflict resulting from the United States asserting governance of subsea mineral exploration and development in international waters under the Deep Seabed Hard Mineral Resources Act (“DSHMRA”); the continued cooperation and alignment of national interests between the United States and the Cook Islands; the Cook Islands’ intention to grant mining licenses in the future; the availability of equipment; the availability of qualified vessel operators and marine contractors; our ability to obtain financing on acceptable terms; currency exchange and interest rates; the impact of competition; the changes and trends in our industry and the global economy; changes in laws, rules, regulations and global standards; our ability to build our market share; our ability to retain key personnel; transaction opportunities, exploration potential, and precious metals prices; the sufficiency of the Company’s amended application for an exploration licence for a defined area of the Clarion-Clipperton Zone in the Pacific Ocean (the “NOAA Application”) under DSHMRA, submitted on July 17, 2026, in responding to the requests for supplemental information in NOAA’s notice to the Company dated May 26, 2026; that NOAA will require no further information from the Company in order to determine the NOAA Application is in full compliance with applicable regulatory requirements; that the federal-agency consultation, antitrust review, public-comment, certification, environmental-review and hearing processes applicable to the NOAA Application will proceed generally in accordance with the indicative regulatory periods described in the Company’s amended and restated annual information form for the year ended December 31, 2025, dated July 27, 2026 (the “A&R AIF”); that NOAA will not identify material deficiencies relating to the Company’s financial responsibility, technical capability, proposed exploration plan, environmental information, proposed licence area or other regulatory requirements that the Company is unable to address; that a licensing process or invitation will be available under the Cook Islands seabed minerals regime on terms allowing the Company to submit an application for an exploration licence in the exclusive economic zone of the Cook Islands (the “Cook Islands Application”); that the Company will be able to complete the technical, financial, environmental, corporate and work-program materials required for the Cook Islands Application within its anticipated timeframe; that the Company will be able to demonstrate access to sufficient financial resources, technical expertise, vessels, equipment, contractors and environmental capabilities to satisfy the applicable NOAA and Cook Islands regulatory requirements; that the Company will obtain sufficient financing to fund the regulatory, environmental, technical and offshore activities contemplated by its NOAA and Cook Islands work programs when required; that the Cook Islands election process and any related government transition will be completed without material delay; that following the election, the Cook Islands authorities will designate additional parcel blocks or areas for subsea mineral exploration and exploitation; that there will be no material change in Cook Islands policy, legislation, licensing criteria or regulatory priorities following the election; that Westwin will continue to intend to make a joint development or other definitive agreement with the Company in the future; that Westwin will be able to perform the proposed joint development program; the proposed joint development agreement will be executed successfully; the existence of a technically and commercially viable processing route; the Company obtaining all licenses, permits and other regulatory approvals required to explore, recover, test mine and harvest subsea polymetallic nodules; and the existence of a sufficient supply of subsea polymetallic nodules for commercial processing in any area for which the Company may obtain subsea mineral exploration or commercial recovery rights.

The forward-looking information in this news release is necessarily based on a number of opinions, estimates and assumptions that we considered appropriate and reasonable as of the date of the A&R AIF. It is also subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the risk factors and uncertainties described under “Risk Factors” in the A&R AIF, as well as risks related to the highly speculative nature of the Company’s business;  risks related to subsea mineral exploration and development operations; risks related to the Company’s limited business history and no history of earnings; risks related to the availability of future financing and the Company’s ability to continue as a going concern; risks related to the Company’s exploration and development activities on the mineral properties; uncertainties regarding the grade and quality of polymetallic nodules; uncertainties regarding the commercial collection of polymetallic nodules; negative perceptions regarding the collection of polymetallic nodules; pressure and lobbying by non-governmental organizations; uncertainties regarding our future reliance on strategic partnerships; uncertainties regarding technology required for our business; uncertainties regarding the treatment and processing of polymetallic nodules; natural hazards and seasonality; expropriation of potential future operating equipment or assets; technological obsolescence; the Company’s dependence on key personnel; risks related to foreign operations; risks related to acquisitions and integration; changes in laws and regulations; risks related to competition; fluctuations in prices of critical minerals, base and precious metals, other commodities and natural resources; legal and litigation risks; uncertainty and volatility related to stock market prices and conditions; dilution of the interests of shareholders; risks related to geopolitical disputes; risks related to the Company’s officers and directors becoming associated with other natural resource companies, which may give rise to conflicts of interest; risks related to climate change; and risks related to pandemics, epidemics or other health crises. With respect to the specific matters addressed in this news release, additional risks and uncertainties include: the risk that NOAA will not determine the NOAA Application to be in full compliance, will not preserve the Company’s priority of right, or will not issue an exploration licence on acceptable terms or at all; the risk that the Cook Islands Application will not be submitted within the anticipated timeframe, will not be accepted as complete, or will not be approved; the risk that the Cook Islands election process or government transition will be delayed or result in material changes to Cook Islands seabed minerals policy, legislation or licensing criteria; the risk that the Company will be unable to demonstrate sufficient financial resources, technical expertise, vessels, equipment, contractors or environmental capabilities to satisfy applicable regulatory requirements; the risk that the Company will be unable to obtain sufficient financing to fund its planned regulatory, environmental, technical and offshore activities; the risk that the Company’s intended offshore operations will be delayed or prevented by regulatory, operational, environmental, financial or other factors; the risks to which Westwin is exposed; and the risk that Westwin is unable to enter into any definitive agreement with the Company in the future for any reason. If any of these risks or uncertainties materialize, or if the opinions, estimates or assumptions underlying the forward-looking information prove incorrect, actual results or future events might vary materially from those anticipated in the forward-looking information. The risks, uncertainties, opinions, estimates and assumptions referred to above and described in greater detail under “Risk Factors” in the A&R AIF should be considered carefully by readers.

Although we have attempted to identify important risk factors that could cause actual results or future events to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information, which speaks only as of the date of this news release. The forward-looking information contained in this news release represents our expectations as of the date of this news release (or as of the date they are otherwise stated to be made), and is subject to change after such date. We disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable Canadian securities legislation.

DALLAS, Sept. 23, 2026 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced that it has formulated and is implementing a comprehensive strategy intended to eliminate both the fraudulent indebtedness asserted by HCLP Nominees, L.L.C. (“HCLP”) and the equity interests in Beneficient and its subsidiaries held by the Company’s former Chief Executive Officer, Brad Heppner, and his affiliated entities (“Heppner Equity Interests”). Through the strategy, the Company also seeks to terminate all other remaining agreements with Heppner or his affiliated entities (“Heppner Agreements”) and have all amounts purportedly owed to them by Beneficient or its subsidiaries under those agreements or otherwise deemed void and unenforceable. The strategy follows Heppner’s May 2026 federal fraud conviction and is a significant component of the Company’s broader effort to transform its balance sheet, simplify its capital structure, and unlock its potential. The Company continues to operate its business and pursue its long-term growth objectives while implementing the strategy.

As previously disclosed, Heppner was convicted on May 7, 2026, of securities fraud, wire fraud and related charges in connection with a fraudulent scheme to enrich himself. The criminal trial revealed overwhelming evidence that Heppner fraudulently concealed his control of HCLP and fabricated the purported HCLP debt. The Company believes the conviction provides substantial support for its position that the purported HCLP debt is invalid and unenforceable. The Company further believes that Heppner’s fraud and other misconduct support substantial claims for damages and other relief, including the elimination of the Heppner Equity Interests and the termination of the Heppner Agreements.

The Company is actively pursuing a consensual resolution with Heppner, with the objective of completing it before his sentencing, currently scheduled for October 21, 2026. The proposed resolution is designed to achieve a complete separation from Heppner, assist him in making restitution to other victims of his criminal conduct, and would include:

• the elimination of the contested HCLP debt, including approximately $130 million of principal and accrued interest;
• the conversion and exchange of all the Heppner Equity Interests, including preferred equity of a Company subsidiary with an aggregate liquidation preference of approximately $850 million, into an aggregate of 162,132 shares of the Company’s Class A common stock;
• the termination or voiding of all remaining contractual arrangements involving Heppner or his affiliated entities and the extinguishment, without payment, of all amounts purportedly owed under those arrangements or otherwise, totaling approximately $88 million.

If completed, the resolution would eliminate substantially all of the Company’s debt; end Heppner’s ownership of the Company’s Class B common stock and his associated super-voting, board-appointment, and consent rights; and resolve the substantial dilution overhang associated with his preferred equity interests. As part of the consensual resolution, the Company would provide customary releases to Heppner and his affiliated entities.

If an acceptable resolution cannot be reached with Heppner, the Company is prepared to swiftly and decisively pursue all available claims and remedies against Heppner, HCLP, and other Heppner-affiliated entities and individuals who received proceeds derived from his fraudulent conduct.

The Company has cooperated fully and transparently with the government’s investigation and prosecution of Heppner and will continue to cooperate, including in connection with the forfeiture or disposition of his or his entities’ assets and efforts to provide restitution to victims.

“Since the conviction, we have focused on pursuing a resolution that fully addresses Mr. Heppner’s misconduct and the harm it caused Beneficient,” said James G. Silk, Chief Executive Officer. “Our objective is a complete separation through the elimination of the purported HCLP debt and all of Mr. Heppner’s remaining equity, contractual and governance interests in the Company. We believe that outcome is both just and necessary to protect Beneficient from further harm. Achieving it would transform our balance sheet, unlock substantial value for our stockholders, and position the Company and its operations to realize its full potential.”

The Company has not entered into a definitive agreement with respect to the proposed resolution, and there can be no assurance that a consensual resolution will be reached or, if litigation becomes necessary, that the Company will achieve its objectives. The Company continues to dispute the validity, enforceability, ownership, amount and value of the purported HCLP debt and all other claims and interests asserted by Heppner or his affiliated entities and will disclose material developments as appropriate.

About Beneficient
Beneficient (Nasdaq: BENF) – Ben, for short – is on a mission to democratize the global alternative asset investment market by providing traditionally underserved investors − mid-to-high net worth individuals, small-to-midsized institutions and General Partners seeking exit options, anchor commitments and preferred liquidity services for their funds − with solutions that could help them unlock the value in their alternative assets.

Its subsidiary, Beneficient Fiduciary Financial, L.L.C., received its charter under the State of Kansas’ Technology-Enabled Fiduciary Financial Institution (TEFFI) Act and is subject to regulatory oversight by the Office of the State Bank Commissioner.

For more information, visit www.trustben.com or follow us on LinkedIn.

Contacts
Matt Kreps: 214-597-8200, mkreps@darrowir.com
Michael Wetherington: 214-284-1199, mwetherington@darrowir.com
Investor Relations: investors@beneficient.com

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the Company’s strategy and objectives concerning the HCLP debt and other Heppner-related interests; the Company’s ability to obtain a judgment or other binding resolution declaring the purported HCLP debt and related liens void, invalid or unenforceable; the potential conversion and exchange of Heppner-related equity interests; and the anticipated effects of these efforts on the Company’s liabilities, collateral, capital structure, financial flexibility, legacy matters and stockholders. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based on management’s current expectations, beliefs, assumptions and information and are not guarantees of future performance or results.

Important factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements include, among others, the outcome and timing of litigation, negotiations and other proceedings involving Heppner, HCLP and related parties; the ability to enter into a definitive agreement with respect to a proposed resolution; the outcome of any appeal or other proceeding relating to Mr. Heppner’s conviction; the risk that the Company is unable to obtain the relief it seeks or otherwise implement its strategy; disputes concerning the validity, enforceability, ownership, amount, value or conversion of the HCLP claims or other Heppner-related interests; the need for third-party or governmental actions, consents or approvals; the accounting and tax treatment of any resolution; the costs and diversion of management’s attention and resources associated with these matters; and the other risks, uncertainties and factors set forth under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and its subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These factors should not be construed as exhaustive and should be read together with the other cautionary statements included in this press release and the Company’s filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. The Company assumes no obligation to update or revise forward-looking statements to reflect actual results, subsequent events or circumstances, except as required by applicable law.

Oral presentation to highlight updated clinical data from 11 patients with Sjögren disease (SjD) treated with AlloNK and rituximab, with six months or more of follow-up

SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that updated clinical data will be delivered in an oral presentation at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026), taking place September 29th – October 2nd at the Cité Internationale Universitaire de Paris:

Abstract Title:	AB-101, an Outpatient-Administered Allogeneic NK Cell Therapy, Combined with Rituximab Generates Robust Efficacy Responses in 11 Patients with Sjögren Disease
Presenting Author:	Guillermo J. Valenzuela, M.D., F.A.C.R. Medical Director, Integral Rheumatology & Immunology Specialists
Session:	Breaking news from clinical trials
Date/Time/Location:	Thursday, October 1, 2026 at 4:30 – 6:00 pm CEST, Amphitheater Adenauer

For more information on this and other abstracts, please visit the ISSjD 2026 abstract book.

About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva is initiating a Phase 3 registrational trial of its lead program, AlloNK^® (also known as AB-101), in refractory rheumatoid arthritis (RA) in the second half of 2026. AlloNK is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved natural killer (NK) cell therapy candidate designed to enhance antibody-dependent cellular cytotoxicity for a range of antibodies, including anti-CD20 antibodies, and drive deep B-cell depletion. Initial clinical data evaluating AlloNK in combination with anti-CD20 antibodies have demonstrated encouraging activity across multiple B-cell-driven autoimmune diseases, together with a tolerability profile supportive of outpatient administration. Artiva is developing AlloNK to drive deep B-cell depletion through a scalable, outpatient-administered treatment regimen compatible with community rheumatology settings. In addition to refractory RA, AlloNK is being evaluated in Sjögren disease, systemic sclerosis and myositis.

Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: the potential benefits, accessibility, practicality, effectiveness, safety and tolerability of AlloNK, including based on interim pooled data across clinical trials, and the potential for administration in an outpatient community setting; the registrational Phase 3 trial for AlloNK, including trial design, expectations for response rates, and timing of initiation, future updates on site activation and enrollment, and topline data readout; and Artiva’s ability to generate sufficient data to support a BLA submission; clinical data expected to be available and presented in refractory RA, SjD and SSc, and the timing of such data disclosures; the number of patients with data from the basket study who would be expected to meet the key eligibility criteria for the planned Phase 3 trial; Artiva’s ability to realize the potential benefits associated with FDA RMAT designation for AlloNK; Artiva’s beliefs regarding its competitive position, including its belief that AlloNK may be the first deep or deep B-cell depleting therapy of any modality to reach patients with, and be approved and commercialized in, refractory RA; and Artiva’s future results of operations and financial position, including cash runway. These forward-looking statements are based on the beliefs of the management of Artiva as well as assumptions made by and information currently available to Artiva. Such statements reflect the current views of Artiva with respect to future events and are subject to known and unknown risks and uncertainties, including, without limitation, risks and delays relating to initiation of the Phase 3 registrational trial, activation of clinical trial sites, patient enrollment and the availability and timing of disclosure of data; risks that future clinical trial results may not be consistent with interim, initial, preliminary, or topline results or results from prior preclinical studies or clinical trials, or with Artiva’s expectations; the risk that the number of patients, or the duration of follow-up for such patients, available for presentation differs from current expectations; the risk that differences exist between trial designs, patient characteristics and other factors for the Phase 3 trial, Artiva-sponsored Phase 2a basket trial and investigator-initiated basket trial, and caution should be exercised in drawing any conclusions from such data across separate trials as such pooling and comparative data is inherently limited and such data may not be directly comparable; the risk that other deep B-cell depleting therapies may advance more rapidly than Artiva currently anticipates, that Artiva’s assessment of publicly disclosed competitor development timelines may be incomplete or inaccurate, and that Artiva may not achieve or be the first to achieve regulatory approval or commercialization of a therapy in this category; the risk that Artiva’s registrational strategy is based in part on recent interactions with the FDA and later feedback from the FDA may be inconsistent with past interactions; Artiva’s ability to obtain adequate financing to fund its planned clinical trials and other expenses; risks inherent in developing product candidates; and risks related to the legal and regulatory framework for the industry. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause Artiva’s actual results to differ from current expectations are discussed in Artiva’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in Artiva’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, Artiva undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investors & Media
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com

Source: Artiva Biotherapeutics, Inc.